Stock ATOS ATOSSA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Atossa Therapeutics, Inc.

Equities

ATOS

US04962H5063

Market Closed - Nasdaq
Other stock markets
 21:00:00 07/05/2024 BST 		5-day change 1st Jan Change
1.7 USD -1.16% Intraday chart for Atossa Therapeutics, Inc. +12.58% +93.18%
05-07 Atossa Therapeutics, Inc. Announces Support of New Breast Cancer Screening Guidelines by U.S. Preventive Services Task Force CI
04-29 Atossa Therapeutics, Inc. Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates and (Z)-Endoxifen CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines
AQ
Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen
AQ
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib in Women with ER+/HER2- Breast Cancer
AQ
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
AQ
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
AQ
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
AQ
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
AQ
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved 'Expanded Access' Program for a U.S. Breast Cancer Patient
AQ
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient
AQ
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
AQ
Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors
AQ
Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting
AQ
Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study
AQ
Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial
AQ
Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial
AQ
Atossa Therapeutics Issues Letter to Shareholders
AQ
Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director
AQ
Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial
AQ
Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
AQ
Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ATOS Stock
  4. News Atossa Therapeutics, Inc.
  5. Press Releases